Tetraphase Misses Primary Endpoint For Phase 3 Trial
September 08, 2015 at 18:54 PM EDT
Shares of Tetraphase are down 80% in after-hours trading after eravacycline missed the primary endpoint for one of its phase 3 trials.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |